Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

NCT02694978 is registered in ClinicalTrials.gov with AMAG Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02694978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02694978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
Lead sponsor
AMAG Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2016
Completion date
July 17, 2017
Enrollment
2,014 (actual)
Sites
127

Conditions

As the registry lists them; a condition with its own page is linked.

iron deficiency anemia